It has been argued that saccade generation is supported by two systems, a'where' system that decides the direction and extent of an impending saccade, and a 'when' system that is involved in the timing of the release of fixation. We evaluated the contributions of these systems to saccade latencies, and used functional MRI to identify the neural substrates of these systems. We found that advance knowledge of the direction and the timing of an impending target movement had both overlapping and discrete effects on saccade latencies and on neural activation. Knowledge of either factor decreased regular saccade latencies. However, knowledge of target direction increased the number of predictive and express saccades while knowledge of target timing did not. The brain activation data showed that advance knowledge of the direction or the timing of the target movement activated primarily overlapping structures. The precentral gyrus, in the region of the frontal eye fields, was more active in conditions in which some aspect of the target movement was predictable than in saccade control and fixation conditions. In the basal ganglia, activation discriminated between advance knowledge of target timing and target direction. The lenticular nuclei were more active when only target timing was known in advance, while the caudate was more active when only target direction was known in advance. These data suggest that the neural structures supporting the 'where' and 'when' systems are highly overlapping, although there is some dissociation sub-cortically. Knowledge of target timing and target direction converge in precentral gyrus, a region where there is strong evidence of context-dependent modulation of neural activity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/brain/awf005 | DOI Listing |
Background: There is an urgent need for new therapeutic and diagnostic targets for Alzheimer's disease (AD). Dementia afflicts roughly 55 million individuals worldwide, and the prevalence is increasing with longer lifespans and the absence of preventive therapies. Given the demonstrated heterogeneity of Alzheimer's disease in biological and genetic components, it is critical to identify new therapeutic approaches.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The University of Texas Health Science Center at Houston, Houston, TX, USA.
Background: Developing drugs for treating Alzheimer's disease (AD) has been extremely challenging and costly due to limited knowledge on underlying biological mechanisms and therapeutic targets. Repurposing drugs or their combination has shown potential in accelerating drug development due to the reduced drug toxicity while targeting multiple pathologies.
Method: To address the challenge in AD drug development, we developed a multi-task machine learning pipeline to integrate a comprehensive knowledge graph on biological/pharmacological interactions and multi-level evidence on drug efficacy, to identify repurposable drugs and their combination candidates RESULT: Using the drug embedding from the heterogeneous graph representation model, we ranked drug candidates based on evidence from post-treatment transcriptomic patterns, mechanistic efficacy in preclinical models, population-based treatment effect, and Phase 2/3 clinical trials.
Background: Although investment in biomedical and pharmaceutical research has increased significantly over the past two decades, there are no oral disease-modifying treatments for Alzheimer's disease (AD).
Method: We performed comprehensive human genetic and multi-omics data analyses to test likely causal relationship between EPHX2 (encoding soluble epoxide hydrolase [sEH]) and risk of AD. Next, we tested the effect of the oral administration of EC5026 (a first-in-class, picomolar sEH inhibitor) in a transgenic mouse model of AD-5xFAD and mechanistic pathways of EC5026 in patient induced Pluripotent Stem Cells (iPSC) derived neurons.
Alzheimers Dement
December 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Background: Focusing on novel AD treatments, the TREAT-AD centers offer an array of free research tools, shared via the AD Knowledge Portal in a Target Enablement Package (TEP). This abstract showcases the research conducted by the IUSM-Purdue TREAT-AD Center, specifically focusing on Targeting class-II PI3K's as a potential breakthrough in AD therapy. Endocytosis within the brain encompasses diverse pathways for internalizing extracellular cargoes and receptors into cells.
View Article and Find Full Text PDFIt is well recognised that Alzheimer's disease and related dementia disorders (ADRD) are associated with very high societal costs. The total global costs of dementia have been estimated to over 1.3 trillion US$ annually (Wimo, Seeher et al.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!